-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $34 at BofA Securities
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $32 at BofA Securities
-
-
-
-
-
-
-
Goldman Sachs on Agios Pharma (AGIO): 'we see a favorable risk-benefit profile'
-
-
-
-
-
-
-
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
-
-
-
-
-
-
-
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
-
-
-
-
-
-
-
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
-
15,661 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

